Dr. Öğr. Üyesi Yasin Sezgin

1. Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer

Sezgin Y., Karhan O., Aldemir M. N., Ürün M., Erçek B. M., Urakcı Z., et al.

Scientific Reports , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

2. Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study

Karhan O., İleri S., Urakçl Z., Arvas H., Klllç D. K., Sezgin Y., et al.

Oncology (Switzerland) , cilt.103, sa.6, ss.498-507, 2025 (SCI-Expanded, Scopus)

3. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

Karhan O., İleri S., Urakçı Z., Sezgin Y., Yıldırım Ü., Ünlü B., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

4. The Role of Bıomarkers In Predıctıng Neoadjuvant Treatment Response In Gastrıc Cancer

Sezgin Y., Ürün M.

Eastern Journal of Medicine , cilt.30, sa.2, ss.245-255, 2025 (Scopus, TRDizin)

5. Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients

Ürün M., Güner G., Sezgin Y., Uysal E., SAKİN A., Kilickap S.

Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus)

6. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience

Sezgin Y., Karhan O., Ileri S., Ebinc S., Tunc S., Urakci Z.

Journal of the College of Physicians and Surgeons Pakistan , cilt.34, sa.8, ss.904-909, 2024 (SCI-Expanded, Scopus)

7. Testis Kanserinde Prognostik Faktörler

Sezgin Y., Karhan O., Biçer A., İleri S., Yerlikaya H., Tunç S., et al.

Turkish Journal of Clinics and Laboratory , cilt.15, sa.2, ss.176-181, 2024 (TRDizin)

8. Mesenteric Panniculitis as a Side Effect of Nivolumab in a Patient with Larnyngeal Cancer

Karhan O., Sezgin Y., Ileri S., Tunc S.

Nigerian journal of clinical practice , cilt.27, sa.6, ss.800-803, 2024 (SCI-Expanded, Scopus)

9. Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma

Guner G., Sezgin Y.

Eurasian Journal of Medical Investigation , cilt.8, sa.1, ss.48-53, 2024 (TRDizin)

10. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

Ürün M., Güner G., Sezgin Y., SAKİN A., Kılıçkap S.

Medical Science Monitor , cilt.30, 2024 (SCI-Expanded, Scopus)

11. Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats

Sezgin Y., Bora E. S., Arda D. B., UYANIKGİL Y., Erbaş O.

Acta cirurgica brasileira , cilt.39, 2024 (SCI-Expanded, Scopus)

12. The impact of timing adjuvant therapy on disease-free survival among patients with stage iib-iiia non-small cell lung cancer receiving platinum- based treatment

ÜRÜN M., SEZGİN Y., UYSAL E.

Turkish Journal of Clinics and Laboratory , cilt.14, sa.3, ss.639-644, 2023 (TRDizin)

13. Comparison of the Efficacy of FOLFIRI and Paclitaxel Chemotherapy Regimens in the Second Line Treatment of Metastatic Gastric Cancer

ÜRÜN M., GÜNER G., SEZGİN Y., YILMAZ ÜRÜN Y., SAKİN A.

Van Yuzuncu Yil University , cilt.16, sa.2, ss.176-182, 2023 (Hakemli Dergi)

14. ADDITIONAL COST OF OVERWEIGHT IN MEDICATION OF CANCER PATIENTS

ÜRÜN M., SEZGİN Y., YILMAZ ÜRÜN Y., UÇAN A., GÜRCÜ S., TUĞRUL F.

Eskisehir Medical Journal, Eskisehir City Hospital , cilt.4, sa.2, ss.107-110, 2023 (Hakemli Dergi)

15. Are Syrian refugee breast cancer patients diagnosed at advanced stage and do they have treatment delays?

Karhan O., Secmeler Ş., Sezgin Y., Ileri S., Yerlikaya H.

Future Oncology , cilt.19, sa.14, ss.983-989, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

16. The Prediction of Overall Survival With The Use of The Sarculator In Operated Soft Tissue Sarcoma of The Extremities: Monocentre Experience

Sezgin Y., Karhan O.

Eastern Journal of Medicine , cilt.28, sa.4, ss.804-809, 2023 (Scopus, TRDizin)

17. The Relatıonshıp Between Pet Ct And Tumor Features In Patıents Wıth Breast Cancer

SEZGİN Y., KARHAN O., İLERİ S., EBİNÇ S., BİLEN E., ÜRÜN M., et al.

Van Tıp Dergisi , cilt.29, 2022 (TRDizin)

18. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy

Ebinç S., Oruç Z., Sezgin Y., Karhan O. u., Bilen E., Yerlikaya H., et al.

Future Oncology , cilt.18, sa.30, ss.3399-3408, 2022 (SCI-Expanded, Scopus)

19. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort

Karaağaç M., Sezgin Y., Eryılmaz M. K., Araz M., Kaplan M. A., Artaç M.

Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1657-1666, 2020 (SCI-Expanded, Scopus)